683 Capital Management’s Array Biopharma Inc ARRY Stock Holding History

683 Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-450,000	Closed	-$7.55M	–	191
2018 Q2	$7.55M	Hold	450,000	–	–	0.51%	41
2018 Q1	$7.34M	Hold	450,000	–	–	0.65%	43
2017 Q4	$5.76M	Sell	450,000 -50,000	-10%	-$569K	0.49%	57
2017 Q3	$6.15M	Buy	+500,000	New	+$4.64M	0.65%	48

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

683 Capital Management's ARRY Position: Q3 2018 in Review

683 Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 450,000 shares — an estimated $7.55M sold.

683 Capital Management first reported a position in ARRY in Q3 2017 and held it in 4 quarters. The position peaked at $7.55M in Q2 2018. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

683 Capital Management reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
683 Capital Management sold 450,000 Array Biopharma Inc shares in Q3 2018, an estimated $7.55M.
683 Capital Management first reported a position in Array Biopharma Inc in Q3 2017 and held it in 4 quarters.
683 Capital Management's Array Biopharma Inc position peaked at $7.55M in Q2 2018.
208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on 683 Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.